Recent findings indicate that advanced stage cancers shun the tumor suppressive actions of TGFβ and inexplicably utilize the cytokine as a tumor promoter.
We investigated the effect of TGFβ1 on the survival and proliferation of invasive prostate (PC3) and bladder (T24) cancer cells. Our study indicated that TGFβ1 decreased cell viability and induced apoptosis in invasive human PC3 and T24 cells via activation of p38 MAPK-JNK-Caspase9/8/3 pathway. Surprisingly, no change in the phosphorylation of pro-survival Akt kinase was observed. We postulate that TGFβ1 pathway may be utilized for specifically targeting urological cancers without inflicting side effects on normal tissues.
Written by:
Al-Azayzih A, Gao F, Goc A, Somanath PR Are you the author?
Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA, United States; Charlie Norwood VA Medical Center, Augusta, GA, United States
Reference: Biochem Biophys Res Commun. 2012 Sep 16. pii: S0006-291X(12)01775-5
doi: 10.1016/j.bbrc.2012.09.035
PubMed Abstract
PMID: 22989755
UroToday.com Investigative Urology Section
